发明名称 |
METHODS AND COMPOSITIONS FOR INCREASING A T-EFFECTOR CELL TO REGULATORY T CELL RATIO |
摘要 |
The present invention is directed to methods for increasing T-cell effector cell to regulatory T cell ratio. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprises an LLO fragment and tumor-associated antigen. |
申请公布号 |
US2017080064(A1) |
申请公布日期 |
2017.03.23 |
申请号 |
US201515123468 |
申请日期 |
2015.03.05 |
申请人 |
ADVAXIS, INS. ;NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMANS SERVICES (DHHS), U.S. GOVERNMEN |
发明人 |
Petit Robert;Wallecha Anu;Chen Zhisong;Berzofsky Jay A;Khleif Samir |
分类号 |
A61K39/00 |
主分类号 |
A61K39/00 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of eliciting an anti-tumor T cell response in a subject having a tumor or cancer, comprising the step of administering to said subject a recombinant Listeria strain comprising a recombinant nucleic acid, said nucleic acid molecule comprising a first open reading frame encoding a recombinant polypeptide and a second open reading frame second open reading frame encoding a metabolic, wherein said recombinant polypeptide comprises a truncated LLO protein fused to a heterologous antigen or fragment thereof, wherein said Listeria comprises a mutation in the endogenous alanine racemase gene (dal), D-amino acid transferase gene (dat), and actA genes, and wherein said T-cell response comprises increasing a ratio of T effector cells to regulatory T cells (Tregs), thereby eliciting an anti-tumor T cell response in said subject. |
地址 |
East Princeton NJ US |